Compass TherapeuticsCMPX
CMPX
About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
Employees: 35
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
40% more capital invested
Capital invested by funds: $147M [Q4 2024] → $205M (+$58.4M) [Q1 2025]
16% more funds holding
Funds holding: 92 [Q4 2024] → 107 (+15) [Q1 2025]
4.99% more ownership
Funds ownership: 73.68% [Q4 2024] → 78.67% (+4.99%) [Q1 2025]
3% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 29
0% more funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]
30% less call options, than puts
Call options by funds: $4.52M | Put options by funds: $6.44M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
149%
upside
Avg. target
$18
647%
upside
High target
$32
1,228%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Michael Schmidt | 315%upside $10 | Buy Maintained | 9 May 2025 |
D. Boral Capital Jason Kolbert | 1,228%upside $32 | Buy Maintained | 28 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis | 896%upside $24 | Buy Reiterated | 21 Apr 2025 |
Leerink Partners Andrew Berens | 149%upside $6 | Outperform Upgraded | 2 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat Details Date: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page.
Positive
Seeking Alpha
1 month ago
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio.
Neutral
GlobeNewsWire
1 month ago
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting.
Neutral
GlobeNewsWire
1 month ago
Compass Therapeutics to Participate in Upcoming May Investor Events
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C.
Neutral
GlobeNewsWire
1 month ago
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting
CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models.
Positive
Finbold
1 month ago
2 Penny stocks to buy in May 2025
Summary ⚈ Market conditions in May create opportunities for penny stock investors.⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects.
Neutral
GlobeNewsWire
1 month ago
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer
BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center.
Neutral
GlobeNewsWire
2 months ago
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025.
Neutral
GlobeNewsWire
2 months ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review.
Neutral
GlobeNewsWire
2 months ago
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC).
Charts implemented using Lightweight Charts™